Synthesis, Bioactivity Evaluation, Molecular Docking, <scp>ADMET</scp> , and Drug‐Likeness Studies of 4‐Chromanone Derivatives Containing a Thiosemicarbazone Moiety as Potential Antioxidants and α‐Glucosidase Inhibitors

ABSTRACT In this study, a novel series of 4‐chromanone derivatives bearing a thiosemicarbazone moiety was rationally designed and efficiently synthesized. The structures of all newly obtained compounds were thoroughly characterized via various spectroscopic methods. The biological evaluation focused on their in vitro antioxidant activity and inhibitory effects against α‐glucosidase. The biological evaluation revealed that several derivatives displayed notable antioxidant and enzyme inhibitory properties. In particular, compound ( E )‐2‐(chroman‐4‐ylidene)‐ N ‐methylhydrazine‐1‐carbothioamide ( 3a ) exhibited remarkable ABTS free radical scavenging ability, achieving an IC 50 of 3.76 μg/mL—outperforming the reference standard trolox, which showed an IC 50 of 8.04 μg/mL. Additionally, compound ( E )‐ N ‐(2‐(chroman‐4‐ylidene)hydrazine‐1‐carbonothioyl)benzamide ( 3j ) emerged as a highly effective inhibitor of α‐glucosidase, with an IC 50 value of 20.17 μg/mL, markedly lower than that of acarbose (237.48 μg/mL), indicating superior inhibitory potency. Molecular docking simulations demonstrated that compound 3a interacts with the active site of NADPH oxidase (PDB: 2CDU) through van der Waals forces, π–sulfur, and π–alkyl contacts. In contrast, compound 3j engaged more extensively with the catalytic pocket of human intestinal α‐glucosidase (PDB: 3TOP), forming multiple interactions such as van der Waals, electrostatic attractions, conventional hydrogen bonds, π–π T‐shaped, and π–alkyl bonds. ADMET profiling and drug‐likeness assessments indicated that these lead compounds exhibit acceptable safety profiles and favorable physicochemical characteristics, aligning well with criteria for prospective therapeutic agents. To the best of our knowledge, this study presents the first comprehensive report on the synthesis, characterization, and biological assessment of this class of 4‐chromanone derivatives bearing a thiosemicarbazone moiety.

Institutions

Publication Details

Journal
Journal of Heterocyclic Chemistry
Published
2025-12-05
DOI
https://doi.org/10.1002/jhet.70146
Citations
1
Primary Topic
Synthesis and biological activity
Type
article
Field-Weighted Citation Impact
0.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Synthesis, Bioactivity Evaluation, Molecular Docking, ADMET , and Drug‐Likeness Studies of 4‐Chromanone Derivatives Containing a Thiosemicarbazone Moiety as Potential Antioxidants and α‐Glucosidase Inhibitors

1 citations
Journal of Heterocyclic Chemistry
Synthesis and biological activity
0.94
article

Synthesis, Bioactivity Evaluation, Molecular Docking, ADMET , and Drug‐Likeness Studies of 4‐Chromanone Derivatives Containing a Thiosemicarbazone Moiety as Potential Antioxidants and α‐Glucosidase Inhibitors

article en
1 citations

Abstract

ABSTRACT In this study, a novel series of 4‐chromanone derivatives bearing a thiosemicarbazone moiety was rationally designed and efficiently synthesized. The structures of all newly obtained compounds were thoroughly characterized via various spectroscopic methods. The biological evaluation focused on their in vitro antioxidant activity and inhibitory effects against α‐glucosidase. The biological evaluation revealed that several derivatives displayed notable antioxidant and enzyme inhibitory properties. In particular, compound ( E )‐2‐(chroman‐4‐ylidene)‐ N ‐methylhydrazine‐1‐carbothioamide ( 3a ) exhibited remarkable ABTS free radical scavenging ability, achieving an IC 50 of 3.76 μg/mL—outperforming the reference standard trolox, which showed an IC 50 of 8.04 μg/mL. Additionally, compound ( E )‐ N ‐(2‐(chroman‐4‐ylidene)hydrazine‐1‐carbonothioyl)benzamide ( 3j ) emerged as a highly effective inhibitor of α‐glucosidase, with an IC 50 value of 20.17 μg/mL, markedly lower than that of acarbose (237.48 μg/mL), indicating superior inhibitory potency. Molecular docking simulations demonstrated that compound 3a interacts with the active site of NADPH oxidase (PDB: 2CDU) through van der Waals forces, π–sulfur, and π–alkyl contacts. In contrast, compound 3j engaged more extensively with the catalytic pocket of human intestinal α‐glucosidase (PDB: 3TOP), forming multiple interactions such as van der Waals, electrostatic attractions, conventional hydrogen bonds, π–π T‐shaped, and π–alkyl bonds. ADMET profiling and drug‐likeness assessments indicated that these lead compounds exhibit acceptable safety profiles and favorable physicochemical characteristics, aligning well with criteria for prospective therapeutic agents. To the best of our knowledge, this study presents the first comprehensive report on the synthesis, characterization, and biological assessment of this class of 4‐chromanone derivatives bearing a thiosemicarbazone moiety.

Journal of Heterocyclic ChemistryVol. 63(3)
Kaili University (CN)
Openalex Percentile: Top 19%
Synthesis and biological activity
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Synthesis, Bioactivity Evaluation, Molecular Docking, <scp>ADMET</scp> , and Drug‐Likeness Studies of 4‐Chromanone Derivatives Containing a Thiosemicarbazone Moiety as Potential Antioxidants and α‐Glucosidase Inhibitors · Journal of Heterocyclic Chemistry (2025) | TGRS Research Map | TGRS